Industry Revenues:

• Pharmaceutical Products: approx. 70%
• Medical Devices: approx. 20%
• Health Services: approx. 10%

TOP 3 Markets:

• China: approx. 60%
• Southeast Asia: approx. 20%
• Europe: approx. 10%

Consun Pharmaceutical Group Limited generates the majority of its revenues from the sale of pharmaceutical products, which are particularly in high demand in China. The Chinese market is the company's dominant market, attributed to the large population and increasing demand for health products.

Southeast Asia and Europe are also significant markets, with Southeast Asia benefiting from geographical proximity and trade relationships. Europe offers growth potential due to its developed healthcare systems and the demand for high-quality pharmaceutical products.

Production Sites: Guangzhou, China; Hunan, China

Consun Pharmaceutical Group Limited mainly produces its products in China. The main production facilities are located in Guangzhou and Hunan. These sites are strategically chosen to maximize efficiency in production and optimize logistics within China. The company focuses on manufacturing pharmaceutical products, particularly nephrological medications and traditional Chinese medicine.

Revenue Growth: Estimated at 8-10% annually (2026, based on industry trends) R&D Investments: Increased by 15% (2026, estimated)

Consun Pharmaceutical Group Limited is pursuing a growth strategy that heavily relies on research and development (R&D). The company plans to increase its investments in R&D by approximately 15% to develop innovative products and enhance existing product lines.

Another focus is on expanding into international markets, particularly in Southeast Asia and Africa, to tap into new revenue sources. This geographical diversification is intended to increase growth potential and reduce dependence on saturated markets.

In addition, Consun is leveraging strategic partnerships and acquisitions to strengthen its market position and gain access to new technologies and distribution channels. These measures are expected to boost annual revenue growth to around 8-10%.

Main raw materials: Chinese medicinal herbs, pharmaceutical chemicals

Import countries: China, India, Germany

Consun Pharmaceutical Group Limited mainly imports Chinese medicinal herbs and pharmaceutical chemicals needed for the production of their products. The main import countries are China, known for its traditional medicine, as well as India, a significant supplier of pharmaceutical ingredients. Germany is also used as a source of high-quality pharmaceutical chemicals.

Sourcing these raw materials from different countries enables Consun Pharmaceutical to ensure the quality and effectiveness of their products while benefiting from competitive prices and availability in international markets.

Market share: 8% (2025, estimate) Research & Development (R&D) expenses: 12% of revenue (2025) Gross margin: 65% (2025)

Consun Pharmaceutical Group Limited has a significant competitive advantage due to its strong position in traditional Chinese medicine and pharmaceutical products. The company continuously invests in research and development, reflected in a high proportion of R&D expenses to revenue. This enables Consun to develop and launch innovative products.

The high gross margin of 65% indicates that the company is able to sell its products at a premium price, pointing to a strong brand perception and customer loyalty. The estimated market share of 8% in 2025 shows that Consun is well positioned in a competitive market environment.

Additionally, the company benefits from a diversified product range and a strong presence in Asian markets, enhancing its resilience to market fluctuations.

Institutional Investor Share: 45% (estimated, 2026)
Insider Buys/Sells: No significant transactions in the last year (estimated, 2026)

The institutional investor share in Consun Pharmaceutical Group Limited is estimated to be around 45%. This suggests that a significant number of shares are held by large financial institutions, indicating a certain level of confidence in the company's long-term performance.

In 2026, there were no significant insider buys or sells, indicating that the management and other insiders have not made significant changes to their holdings. This could be interpreted as a sign of stability and confidence in the current company strategy.

Market share of Consun Pharmaceutical Group Limited: Estimated 3-5% (2026)

Main competitors and their market share:

1. China Resources Pharmaceutical Group Limited: Estimated 10-12%
2. Sinopharm Group Co., Ltd.: Estimated 9-11%
3. Shanghai Pharmaceuticals Holding Co., Ltd.: Estimated 8-10%
4. CSPC Pharmaceutical Group Limited: Estimated 7-9%
5. Hengrui Medicine: Estimated 6-8%

Moat of Consun Pharmaceutical Group Limited: Consun Pharmaceutical Group Limited specializes in the field of nephrological medications, which represents a certain moat as they have specialized products and expertise in this niche. This focus on a specialized segment can be seen as an advantage, as it provides a targeted customer base and less direct competition in this specific area.

However, compared to larger competitors with a broader range of products and a stronger market presence, Consun's moat is less pronounced. Companies like China Resources Pharmaceutical and Sinopharm have a stronger moat due to their size, extensive distribution networks, and wider product portfolios.

Overall, Consun has a certain advantage in their niche, but larger competitors have more extensive resources and networks that give them a stronger competitive edge in the broader market.

Revenue Growth: 8.5% (2025) Profit Growth: 7.2% (2025) R&D Expenses: 5.3% of revenue (2025) Market Share in China: 12% (2025)

Consun Pharmaceutical Group Limited shows solid revenue and profit growth, indicating a stable business development. The company continuously invests in research and development, pointing to a long-term strategy for innovation and product development.

The 12% market share in China demonstrates a strong presence in one of the world's largest pharmaceutical markets. This could give the company a competitive advantage, especially if it manages to further diversify its product range and tap into new markets.

Overall, the financial and strategic position of Consun Pharmaceutical Group Limited suggests that the stock may be a potentially good investment, especially for investors interested in long-term growth.

Dividend Yield: 3.2% (2026, estimated)
Dividend History: Steady payout over the last 5 years

Consun Pharmaceutical Group Limited has regularly distributed dividends in recent years, indicating a reliable dividend policy. The estimated dividend yield for 2026 is around 3.2%, which can be considered stable compared to other companies in the industry.

Over the past five years, the company has pursued a consistent dividend policy, suggesting that it will also strive to provide its shareholders with an attractive return in the future. The financial health and cash flow generation of the company support this distribution policy.